Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q4 FY24 results · Jan–Mar 2024
Divi's Laboratories reported revenue from operations of ₹2,303.00 crore (up 18.1% from Q4 FY23) and net profit of ₹538.00 crore (up 67.6% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,303.00 | 1,950.77 | +18.1% | 1,855.00 | +24.2% |
| Other income | 79.00 | 66.15 | +19.4% | 95.00 | −16.8% |
| Total income | 2,382.00 | 2,016.92 | +18.1% | 1,950.00 | +22.2% |
| Profit before tax | 713.00 | 466.48 | +52.8% | 489.00 | +45.8% |
| Net profit for the period | 538.00 | 320.97 | +67.6% | 358.00 | +50.3% |
| EPS, basic (₹) | 20.25 | 12.09 | +67.5% | 13.50 | +50.0% |
| Net margin (%) | 23.4 | 16.5 | 19.3 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,259.00 | 1,908.17 | +18.4% | 1,808.00 | +24.9% |
| Other income | 79.00 | 66.15 | +19.4% | 94.00 | −16.0% |
| Total income | 2,338.00 | 1,974.32 | +18.4% | 1,902.00 | +22.9% |
| Profit before tax | 700.00 | 468.04 | +49.6% | 490.00 | +42.9% |
| Net profit for the period | 531.00 | 318.79 | +66.6% | 358.00 | +48.3% |
| EPS, basic (₹) | 19.99 | 12.01 | +66.4% | 13.50 | +48.1% |
| Net margin (%) | 23.5 | 16.7 | 19.8 |
Consolidated
- Filed with BSE
- 27 May 2024, 14:38 IST
- Board meeting
- 25 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 May 2024, 14:38 IST
- Board meeting
- 25 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE